RE:GBM PH1The below two sentences taken from the Lung Cancer Research PR of 8/8.
"A majority of all cancers demonstrate an upregulation of the transferrin receptor (“Tf-R”), as malignant cells require an abundance of iron (Fe3+) for proliferation; thus, the prevalence of the Tf-R has been directly correlated to increasing tumour: grade, stage, progression and metastasis.
an evaluation of the TfR by flow cytometric analysis in three human cancer cell lines; specifically: H2170 (lung squamous cell carcinoma), H460 (large cell lung cancer carcinoma) and A549 (lung adeno carcinoma) showed almost 100% of lung cancer cells express the TfR."
If the GBM trial will be utilizing Rutherin and X-rays why not proceed with a lung cancer trial using with the same? Seems like a hop skip and jump to get there if the GBM human trial is approved. Originally RW stated they went with the bladder because it was easy to access. Now with Rutherin and X-ray activation there is no access or surgical suite issue any more.
Could we see GBM and lung cancer as the two indications in Q4? That would certainly get some attention.
quote=enriquesuave]My guess is that they will try Rutherin and X-rays on a larger animal group such as dogs with GBM and with that data will apply for PH1. Could be sooner than we think. Just a guess, but they are going with the least invasive Method and fastest route to PH1trial for GBM. No ITA or hardware to get approved. Just need sufficient safety data to try on Humans. Efficacy will be at the Rendezvous.IMHO[/quote]